RadioMedix Inc. launches SmartMedix™ synthesizers powered by Trasis in USA

Share Article

RadioMedix Inc. announced today that the company was granted an exclusive distribution rights for all Trasis’s “AllinOne” series radiosynthesizer products in the United States. Radiosynthesizers powered by Trasis will be marketed under the RadioMedix’s brand name “SmartMedix™” in U.S.A.

RadioMedix Inc. announced today that the company was granted an exclusive distribution rights for all Trasis’s “AllinOne” series radiosynthesizer products in the United States. Radiosynthesizers powered by Trasis will be marketed under the RadioMedix’s brand name “SmartMedix™” in U.S.A. This will include a platform of specially designed automated synthesizers for radiopharmaceuticals used for both clinical and research applications. The SmartMedix™ system gathers both radio-synthesizer and reformulation modules that are compatible for synthesis of 68Ga, 18F, 64Cu 68Ge/68Ga generators, and it can be customized in different configurations based on the customers’ and 177Lu-labeled radiopharmaceuticals. This system is compatible with all the currently available needs. SmartMedix™ is a versatile, user-friendly automated, cassette-based, and GMP compliant system that allows implementing the simplest to the most tedious radiochemistry protocols on the same instrument. RadioMedix Inc. scientists will provide radiopharmaceutical and after-sales technical support for SmartMedix™ modules.

Dr. Delpassand, CEO and Chairman of RadioMedix, explained: “SmartMedix™ automated modules produce high purity radiotracers in reproducible manner and at the lowest radiation exposure to the operators. SmartMedix™ simplifies the production of radiopharmaceuticals for research applications and also provides the full GMP documentations for batch book recording for clinical trials. We are excited to offer this excellent technology for manufacturing PET radiopharmaceuticals to our research and clinical communities in USA.”

Jean-Luc Morelle, PhD., co-founder of Trasis S.A. in Belgium said: "Our distribution agreement with RadioMedix is an important step in the deployment of our technology abroad. It will ensure that every US user will receive the support he deserves. With our complimentary skills, instrumentation and process optimization at Trasis and drug development at RadioMedix, our similar size companies share the same eagerness to bring new imaging and therapy solutions fast and safely to the physicians and to their patients."

About RadioMedix Inc.
RadioMedix, Inc. is a biotechnology company, based in Houston, Texas, focused on innovative targeted radiopharmaceuticals for diagnosis, monitoring and therapy of cancer. The company is commercializing generator-produced radiopharmaceuticals based on Gallium-68 chemistry. RadioMedix is in late-stage development of a new radiolabeled analog targeting metabolic pathway, GlucoMedix, which is based on its patented DO2A-chelation technology. RadioMedix is introducing the SmartMedix™ automated laboratory system for synthesis of PET tracers for the research and clinical markets. RadioMedix has also established two service facilities for academic and industrial partners: cGMP Manufacturing Suite for clinical probe development and Molecular Imaging Facility for evaluation of agents in animal models.
http://www.radiomedix.com

About Trasis S.A.
Trasis SA specializes in the development and manufacturing of radiopharmaceutical equipment.

The company was created in 2004 with its headquarters in Liege, Belgium. Trasis SA builds on the experience of its founders in major engineering and radiopharmaceutical companies and it supplies innovative and reliably designed systems that meet today’s and tomorrow’s needs. From accelerator or generator output to dose administration systems, Trasis can provide the best products and service adapted to your needs.
http://www.trasis.com

Share article on social media or email:

View article via:

Pdf Print

Contact Author

Izabela Tworowska, PhD
Visit website